Home > Stemline Therapeutics Salary

Stemline Therapeutics Salary

  • 94
  • 39
  • 76
Stemline Therapeutics average salary is $133,332, median salary is $130,000 with a salary range from $119,995 to $150,000.
Stemline Therapeutics salaries are collected from government agencies and companies. Each salary is associated with a real job position. Stemline Therapeutics salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Total 3 Stemline Therapeutics Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Dentist 150,000-150,000 Owasso, OK, 74055 2018 Stemline Therapeutics Dentist Salaries (3)
Stemline Therapeutics Owasso, OK Salaries
Dentist 119,995-119,995 Edmond, OK, 73003 2016 Stemline Therapeutics Dentist Salaries (3)
Stemline Therapeutics Edmond, OK Salaries
Dentist 130,000-130,000 Owasso, OK, 74055 2015 Stemline Therapeutics Dentist Salaries (3)
Stemline Therapeutics Owasso, OK Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

Stemline Therapeutics salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
Stemline Therapeutics Jobs
See more Stemline Therapeutics Jobs»
Search All Jobs

JobCompare – Find open jobs faster
Stemline Therapeutics... Information
  • Stemline Therapeutics Inc
  • Industry: BioTech/Drugs
  • City: New York, NY
  • Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company and a leading developer of novel oncology compounds directed to cancer stem cell targets. Stemline¡¯s lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human trial.